Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 2,013
Change Today +91.00 / 4.73%
Volume 16.1K
CGEN On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
Tel Aviv
As of 9:24 AM 08/30/15 All times are local (Market data is delayed by at least 15 minutes).

compugen ltd (CGEN) Snapshot

Open
$2,044
Previous Close
$1,922
Day High
$2,044
Day Low
$2,001
52 Week High
01/12/15 - $3,770
52 Week Low
08/24/15 - $1,790
Market Cap
975.9M
Average Volume 10 Days
57.4K
EPS TTM
$-1.52
Shares Outstanding
48.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for COMPUGEN LTD (CGEN)

compugen ltd (CGEN) Related Businessweek News

No Related Businessweek News Found

compugen ltd (CGEN) Details

Compugen Ltd., a drug discovery company, engages in the research, development, and commercialization of therapeutic and product candidates primarily in the United States, Europe, and Israel. It primarily focuses on the discovery and development of monoclonal antibodies (mAbs) and therapeutic proteins to address the unmet needs in the fields of oncology and immunology. The company’s therapeutic proteins pipeline includes CGEN-15001, CGEN-15021, CGEN-15091, CGEN-15031, and CGEN-15051 for the treatment of a range of diseases including cancer, autoimmune and infectious diseases, blood-related disorders, and others. Its monoclonal antibody therapy product candidates comprise CGEN-15001T, CGEN-15022, CGEN-15049, CGEN-15027, CGEN-15092, and CGEN-15052. The company was incorporated in 1993 and is headquartered in Tel Aviv, Israel.

83 Employees
Last Reported Date: 03/12/15
Founded in 1993

compugen ltd (CGEN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $295.8K
Vice President of Antibody Research and Devel...
Total Annual Compensation: $274.8K
Vice President of Research & Discovery
Total Annual Compensation: $193.6K
Vice President of R&D Planning and Control
Total Annual Compensation: $154.1K
Compensation as of Fiscal Year 2014.

compugen ltd (CGEN) Key Developments

Compugen Ltd. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Compugen Ltd. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, revenues were $0.223 million compared with $1.964 million a year ago. Operating loss was $6.953 million compared with $3.318 million a year ago. Net loss for the second quarter of 2015 was $6.8 million, or $0.14 per diluted share, compared with a net loss of $2.3 million, or $0.07 per diluted share, for the comparable period in 2014. Net loss before taxes was $6.808 million compared with $2.259 million a year ago. The decrease in revenues is attributable mainly to the milestone payment in the amount of $1.2 million received in the second quarter of 2014 and a reduction in the recognition of the non-refundable upfront payment for the second quarter of 2015 and six months ending June 30, 2015, both under the August 2013 collaboration and license agreement with Bayer. For the six months, revenues were $0.736 million compared with $4.097 million a year ago. Operating loss was $13.275 million compared with $6.629 million a year ago. Net loss for the six months ending June 30, 2015 was $13.0 million, or $0.26 per diluted share, compared with a net loss of $4.2 million, or $0.09 per diluted share, for the comparable period in 2014. The significant increase in net loss for the comparable period, largely relates to a decrease in revenues as noted above, and an increase in the company’s discovery and development activities relating to its Pipeline Program candidates. Net loss before taxes was $12.951 million compared with $4.157 million a year ago.

Compugen Ltd. to Report Q2, 2015 Results on Aug 04, 2015

Compugen Ltd. announced that they will report Q2, 2015 results at 9:45 AM, US Eastern Standard Time on Aug 04, 2015

Compugen Ltd., Q2 2015 Earnings Call, Aug 04, 2015

Compugen Ltd., Q2 2015 Earnings Call, Aug 04, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CGEN:IT 2,013.00 +91.00

CGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CGEN.
View Industry Companies
 

Industry Analysis

CGEN

Industry Average

Valuation CGEN Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COMPUGEN LTD, please visit www.cgen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.